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ABSTRACT
Objective: Adalimumab has proven effective in
psoriasis; however, secondary failure may result from
the drug’s immunogenicity. Prevalence data on the
immunogenicity of biologicals, and of adalimumab in
particular, are highly variable. We investigated the
prevalence of anti-adalimumab antibodies and the
association with clinical indexes and tumour necrosis
factor α (TNFα) serum levels in psoriatic patients.
Design: Case–control, longitudinal.
Setting: Single centre.
Participants: Patient groups: I (n=20) receiving
biological therapies after switching from adalimumab;
II (n=30) ongoing adalimumab therapy; III (n=30)
novel adalimumab therapy; IV (n=15) biological
therapies other than adalimumab.
Healthy subjects: (group V; n=15) never treated with
immunosuppressants or biologicals.
Interventions: All groups were tested at enrolment.
Group II was also tested at 12 months, and group III at
1, 3, and 6 months.
Primary and secondary outcome measures:
Standard clinical evaluations (Psoriasis Area Severity
Index (PASI)), blood samples and two-site ELISA-
based measurement of serum adalimumab trough
levels, anti-adalimumab antibodies and TNFα.
Results: The false-positive rate was 23% for
adalimumab detection and 22% for anti-adalimumab
antibodies in patients naïve to adalimumab. Spurious
positivity for anti-adalimumab antibodies (one-time-
point positivity in group III during follow-up)
accounted for 33% of the total. The prevalence of anti-
drug antibodies was highest (87%) in group I patients.
No correlations were found between the presence of
anti-adalimumab antibodies or adalimumab levels and
changes in PASI scores.
Conclusions: High variability of results, high
prevalence of false-positives and lack of association
between anti-adalimumab antibodies and TNFα level/
PASI score limit this assay’s usefulness. Accurate
clinical evaluation is key to early identification of
treatment failures.
INTRODUCTION
Biological therapies have revolutionised the
treatment of inﬂammatory and autoimmune
diseases and improved the quality of life of
patients over the last decade. By interfering
with the activity of key mediators (eg, inﬂam-
matory cytokines), biologicals slow down
aberrant immune response, thus limiting, or
even blocking, the progression of disease in
the majority of treated patients.1
Psoriasis is a complex disease characterised
by interactions between certain genes and
environmental factors, leading to an imbal-
ance in immune activation towards the
expression of inﬂammatory mediators known
to contribute to the pathogenesis of psoria-
sis.2 Among the mediators successfully tar-
geted by therapeutic agents3 4 is tumour
necrosis factor (TNF). Anti-TNF drugs, ini-
tially developed to treat other inﬂammatory
diseases (ie, rheumatoid arthritis), are now
used in the treatment of psoriasis and psori-
atic arthritis.5 Available clinical data indicate
Strengths and limitations of this study
▪ The main limitations of this study are: the small
number of patients in each group, the correlation
analysis between objectively measured para-
meters (anti-adalimumab antibodies, serum ada-
limumab trough levels) and a semi-quantitative
subjective disease severity index (PASI), and the
presence of a subset of patients with psoriatic
arthritis.
▪ The main strength of this study is the exclusion
of possible confounding factors that might have
affected the analysis.
▪ Evaluation of four different patient groups: group I
previously treated with adalimumab, group II on
adalimumab therapy and followed up for
12 months, group III started on adalimumab
therapy and followed up for 12 months, and group
IV on biological therapies other than adalimumab.
▪ Exclusion of modifying factors: no cotreatment
with immunosuppressants or previous treat-
ments with other biologicals.
▪ Evaluation of healthy subjects never treated with
immunosuppressant drugs and biologicals and
psoriatic patients under therapy with biologicals
other than adalimumab.
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that response to treatment with anti-TNF agents is effect-
ive in 60–70% of treatment-naïve patients with immune-
mediated inﬂammatory diseases. Secondary failure
occurs in a certain percentage of cases when6 immune
reactions against the drug are produced by antibodies
targeting the therapeutic molecule (antidrug antibodies
—ADA).7 8 Although all protein-based drugs (including
anti-TNF agents) are potentially immunogenic, certain
structural features of the drug make this event more
probable. For instance, the presence of non-human (ie,
murine) portions within the molecule increases the
probability an immune response will be elicited:
the greater the relative weight of non-human sequences,
the greater the immunogenic potential of the molecule.
By this view, as conﬁrmed by previous studies, chimeric
molecules would be generally more immunogenic than
humanised and human ones.9 10
Anti-TNF agents differ structurally from one another:
full-length bivalent IgG antibodies (chimeric: inﬂiximab
(IFX), human: adalimumab (ADL), golimumab), poly-
ethylene glycol-conjugated humanised FabI (certolizumab
pegol) or human Fcγ1-conjugated TNF receptor (TNFR)
2 (etanercept (ETN)).11 Among anti-TNF agents, ADL
(Humira, Abbvie) has been proven effective in the bio-
logical treatment of psoriasis.12–14 However, although ADL
is a fully human monoclonal antibody against TNF and its
immunogenic potential is putatively low, the prevalence
data of ADL immunogenicity ranges from 6.4% to 44.8%
in psoriasis15 and from 0.04% to 87% in the whole set of
ADL-treatable diseases.16 Such wide variability, reviewed by
several studies, renders this information useless in clinical
practice. Moreover, it contrasts with clinical evidence that
ADL is highly effective and safe. Indeed, if an acceptable
probability of eliciting immune response lies in the lower
quartile of this range, in line with clinical observations, it is
evident that the upper half of these ranges contemplates a
very high probability of immune response, and conse-
quently of secondary therapeutic failure, which is not
coherent with reality and, more importantly, would be
unacceptable for patients.
There are several possible reasons for this variability.
Some have been adequately explained in recent studies
(eg, blood sampling at the time of drug trough levels,
regular frequency of administration, no change in
doses)7 whereas other causes have not been fully eluci-
dated. For instance, cotreatment (ie, immunosuppres-
sant drugs—ISs) is variously deﬁned across studies. ISs
are known to modify immune response and the
response to potential immunogens.17 18 This is problem-
atic when patients receiving anti-TNF therapy alone or
according to different anti-TNF-ISs cotreatment proto-
cols (simultaneous, alternate, cyclic) are grouped
together. Moreover, the potential modifying effects of
previous biological therapies are often insufﬁciently
taken into account even though multiple treatments are
known to predispose to immunogenicity.15
Critical in this context are methodological issues
coupled with currently available technologies used to
detect/measure ADAs. Different methods have different
pitfalls, including low speciﬁcity, interference by
endogenous compounds and tendency to generate false-
positive results.7 10 As recent studies have failed to fully
clarify the clinical relevance of ADAs,19 the question
remains open whether a real relationship exists between
ADA expression and therapeutic failure. Therefore, the
aim of this study was to overcome the technical and clin-
ical limitations mentioned above by focusing on ADL
treatment for psoriasis in well-characterised groups of
ADL-treated patients (formerly treated, under treatment
and newly treated), patients treated with other biologi-
cals and healthy controls.
MATERIALS AND METHODS
Patient population
Patients with a diagnosis of cutaneous psoriasis and
healthy controls were enrolled at the Department of
Dermatology and Venereology of I.R.C.C.S. Istituto
Ortopedico Galeazzi (Milan, Italia). The study was con-
ducted in accordance with the tenets of the Declaration
of Helsinki. Written consent to the use of clinical data in
aggregate form was obtained from all patients after
being informed about the study procedures.
Patient selection criteria were as follows: absence of
comorbidities such as diabetes mellitus, genetic diseases,
autoimmune diseases, acute and chronic systemic or
cutaneous infections during sample collection, negative
results at screening for hepatitis B virus, hepatitis C
virus, HIV and tuberculosis infections. Patients receiving
treatment with either IS drugs (cyclosporine A, metho-
trexate) or systemic corticosteroids during anti-TNF
therapy or within 3 weeks before the beginning of the
therapy were also excluded from the study.
Administration of ADL therapy followed the standard
schedule: 80 mg s.c. in the ﬁrst infusion, 40 mg after
1-week, and then 40 mg every 15 days. The clinical sever-
ity of psoriasis was scored using the Psoriasis Area
Severity Index (PASI) at each visit.20
The study sample was composed of four patient
groups plus one group of healthy volunteers that served
as controls.
▸ Group I (ex-ADL; n=20): Previously treated with ADL,
which had been discontinued at least 6 months
before enrolment in the study, and on treatment with
another biological agent (IFX or ETN) at the time of
enrolment. Group I was tested once at enrolment.
▸ Group II (on-ADL; n=30): Under ADL treatment for at
least 6 months prior to the time of enrolment and
continued with therapy for at least 12 months after
recruitment. Group II was tested twice, at enrolment
and at 12 months.
▸ Group III (naïve; n=30): Never treated with any bio-
logical, were started on ADL therapy and continued
with therapy for at least 6 months. Group III was
tested four times: at enrolment, before the start of
therapy (T0), at 1 (T1), 3 (T3) and 6 (T6) months of
treatment.
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▸ Group IV (on-BIO; n=15): Under treatment, or previ-
ously treated, for at least 6 months, with biologicals
other than ADL (IFX or ETN) and never treated
with ADL. Group IV was tested once at enrolment.
▸ Group V (CTRL; n=15): Healthy controls with no
chronic condition and never treated with ISs or biolo-
gicals. Group V was tested once at enrolment.
Age at recruitment ranged from 19 to 79 years in the
psoriatic patient groups and from 25 to 65 years in the
control group. Table 1 presents the study population
demographics and clinical features.
Blood sampling
In the patients receiving biological agents (groups I, II,
III, IV), blood samples were collected immediately
before drug injection at the time of drug trough level.
Non-fasting blood samples were collected in SSTII BD
Vacutainers (Becton Dickinson, Franklin Lakes, New
Jersey, USA); serum was separated by centrifugation
(1200 g, 10 min at 4°C) and stored at −80°C until
assayed. Serum ADL (sADL) trough levels and anti-ADL
antibody (sAAA) levels were measured in duplicate
using speciﬁc two-site (bridging) immunoassays
(Promonitor ADL/AAA, Progenika Biopharma, Derio,
Spain). Serum TNFα (sTNFα) was measured using an
ultrasensitive ELISA kit (Novex, Life Technologies,
Carlsbad, California, USA). The lower limit of
detection (LLD) of the assays and the intra-assay vari-
ability (CVi) and the interassay variability (CVb) were
3.5 AU/mL, 6.6% and 6.6% for sAAA, respectively;
0.024 μg/mL, 6.1% and 5.1% for sADL, respectively; and
0.09 pg/mL, 6.7% and 9.7% for TNFα, respectively. All
samples were tested at least twice for conﬁrmation.
Testing for antinuclear antibodies (ANA) and C reac-
tive protein (CRP) was ordered by the patients’ phys-
ician as needed and according to clinical practice. All
tests were performed by accredited laboratories.
Statistical analysis
Normality of distribution was tested using the
D’Agostino-Pearson test. As the values were non-
parametrically distributed, quantitative parameters are
expressed as the median (range) in the descriptive ana-
lysis. Intergroup comparisons were performed using the
Kruskal-Wallis test. Spearman’s rank correlation test was
used to evaluate correlations. Correlations were consid-
ered signiﬁcant when r≥0.25 for p<0.05. Analysis was
carried out using GraphPad Prism V.6.01 (GraphPad
Software, La Jolla, California, USA). Signiﬁcance was set
at p<0.05.
RESULTS
Immunogenicity of ADL
Results are presented in table 2. Detectable sADL levels
were found in at least one assay of samples from eight
out of 20 ex-ADL patients (group I), but only in one of
these eight was the result replicated in the subsequent
tests. The variability between the tests, performed on ali-
quots of the same sample (interassay variability), was
very high (interassay mean fold change 50). Notably, the
time since discontinuation of ADL therapy ranged from
13 months to 7 years in the patients in which positivity
was not conﬁrmed and was only 6 months in the one
patient in whom ADL positivity was conﬁrmed. sAAA
were detectable in 13 out of 20 ex-ADL patients.
Although the interassay variability was high (interassay
mean fold change 23), all positive results were
replicated.
At recruitment, 26 (87%) on-ADL patients (group II)
had detectable trough ADL concentrations (5.8 μg/mL
(range, 0.1–12.0)). The four patients with undetectable
sADL had, however, detectable sAAA, as did two of those
with detectable sADL (sAAA 219.3 AU/mL (range,
141.0–822.2)). At recruitment, all group II patients were
classiﬁed as responders. There was no signiﬁcant differ-
ence in the median PASI score between the
sAAA-negative patients (1.1 (range, 0–14)) and the
sAAA-positive patients (4.0 (range, 0.2–8.0); p=0.069) or
in the TNFα concentration (0.12 pg/mL (range, 0–1.42)
vs 0.04 pg/mL (range, 0–0.54); p=0.471) and the CRP
concentration (0.12 mg/dL (range, 0–8.0) vs 0.46 mg/
dL (range, 0.13–0.80)), respectively. Furthermore, the
percentage of arthropathic patients was 50% among the
patients that tested sAAA-negative and sAAA-positive.
After 12 months of ADL therapy, the median change in
PASI score was 0.1 in the patients who had tested
sAAA-negative at recruitment and 0.2 in those who had
tested sAAA-positive at recruitment (p=0.673). Two
patients tested sAAA-positive at 12 months: one with no
change in PASI score and one with a decrease to −0.3.
Two patients who had tested sAAA-positive at recruit-
ment had no detectable sAAA at 12 months; the PASI
score was unchanged in one patient and increased by
0.8 in one patient. Finally, two patients remained
sAAA-positive during the study; the PASI score was
decreased by 1 point in one patient and remained
unchanged in one patient.
Also, in group II the concordance between replicated
tests was low: one patient tested positive for sADL and
two patients for sAAA at the ﬁrst test and negative at the
three subsequent tests. The mean fold change between
replicated tests was 34 for sADL and 26 for sAAA.
Among the subjects never exposed to ADL, 14 tested
sADL-positive (three from group III (naïve) at T0, six
from group IV (on-BIO) and ﬁve from group V
(CTRL)) and 13 tested sAAA-positive (one from group
III at T0, seven from group IV and ﬁve from group V).
The positive samples were detected in one or more of at
least two replicated assays. The overall frank false-
positivity rate was 23% for sADL and 22% for sAAA.
During the 6-month follow-up, 13 out of 30 (43%)
group III patients had detectable sAAA levels at one or
more time points after T0. Notably, in all these cases but
three, sAAA expression was spurious because it was
found at a single time point (at either 1 or 3 months).
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Table 1 Characteristics of the study population at recruitment
Cases Controls
Total patients,
n=95
Group I ex-ADL,
n=20
Group II on-ADL,
n=30
Group III naïve,
n=30
Group IV on-BIO,
n=15
Group V CTRL,
n=15
Age, median (range) years 48.0 (19.0–79.0) 49.5 (28.0–79.0) 48.0 (21.0–65.0) 48.5 (19.0–66.0) 47.0 (29.0–70.0) 34 (25–65)
Male, n (%) 71 (74.7) 14 (70.0) 28 (93.3) 24 (80.0) 5 (33.3) 7 (46.7)
Female, n (%) 24 (25.3) 6 (30.0) 2 (6.7) 6 (20.0) 10 (76.7) 8 (53.3)
BMI, median (range) kg/m2 26.8 (18.0–44.0) 28.0 (20.0–39.4) 26.5 (20.5–32.8) 16.2 (20.0–44.0) 26.5 (18.0–39.4) 23 (19.0–27.0)
Disease duration, median
(range) years
20.0 (4.0–60.0) 16.0 (7.0–56.0) 20.0 (4.0–60.0) 18.5 (4.0–60.0) 32.0 (10.0–56.0) –
PASI, median (range) 3.0 (0.0–24.0) 2.0 (0.0–24.0) 1.1 (0.0–14.0) 12.2 (2.5–22.0) 0.0 (0.0–14.0) –
PsA, n (%) 45 (47.4) 10 (50.0) 15 (50.0) 11 (36.6) 9 (60.0) –
Previous treatments, n (%) 95 (100) 20 (100) 30 (100) 30 (100) 15 (100) –
Retinoids 8 (8.4) 3 (15.0) 2 (6.7) 1 (3.3) 2 (13.3) –
UV B 19 (20.0) 5 (25.0) 6 (20.0) 8 (26.7) 0 (0) –
MTX 76 (80.0) 13 (65.0) 25 (83.3) 26 (86.7) 12 (80.0) –
CsA 62 (65.3) 12 (60.0) 21 (70.0) 21 (70.0) 8 (53.3) –
ETN 26 (27.4) 11 (55.0) 9 (30.0) 0 (0) 6 (40.0) –
IFX 15 (15.8) 1 (5.0) 2 (6.7) 0 (0) 12 (80.0) –
EFZ 7 (7.4) 2 (10.0) 2 (6.7) 0 (0) 3 (20.0) –
ADL 20 (21.0) 20 (100) 0 (0) 0 (0) 0 (0) –
USK 5 (5.3) 3 (15.0) 0 (0) 0 (0) 2 (13.3) –
GOL 1 (1.0) 0 (0) 1 (3.3) 0 (0) 0 (0) –
ADL, adalimumab; BMI, Body Mass Index; CsA, cyclosporine A; EFZ, efalizumab; ETN, etanercept; GOL, golimumab; IFX, Infliximab; MTX, methotrexate; PASI, Psoriasis Area Severity Index;
PsA, psoriatic arthritis; USK, ustekinumab.
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Only ﬁve patients (16.7%) tested sAAA-positive at
6 months, which could have been due to a real immuno-
genic event. The median change in PASI scores between
the patients testing sAAA-negative or sAAA-positive (at
least once) was −12.0 (range, −4.0 to −22.0) and −9.3
(range, 0.0 to −21.0), respectively, without any signiﬁ-
cant difference (p=0.105). No signiﬁcant difference in
PASI scores was observed when the patients with no
sAAA and those spuriously expressing sAAA were com-
pared with those with detectable sAAA only at 6 months
(−12.0 (range, −2.0 to −22.0) versus −9.3 (range, 0.0 to
−15.1); p=0.273). The variability between replicates was
very high, with an interassay mean fold change of 48 for
sADL and 25 for sAAA, as was the intra-assay variability
(concordance between duplicates), adjusted for the rela-
tive dilution factor, which ranged from 10% to 83% for
both tests.
Correlation between immunogenicity and humoral
and clinical parameters
There was a statistically signiﬁcant correlation between
positivity for sAAA (but not the titre) and TNFα levels in
group I patients (r=0.56; p=0.025). In group II, there
was a clinically signiﬁcant correlation between CRP con-
centration and duration of disease (r=0.54; p=0.032) and
an inverse correlation between the presence of psoriatic
arthritis and age (r=−0.42; p=0.015). sAAA positivity and
concentrations were inversely correlated with age (r=
−0.37; p=0.036) and sADL (r=−0.52; p=0.002). The PASI
score was inversely correlated with sAAA concentration
(r=−0.38; p=0.033) and with sADL concentration (r=
−0.65; p<0.001). In group III, sAAA positivity was
inversely correlated with detectable levels of sADL (r=
−0.27; p=0.003). Neither sAAA nor sADL concentration
was correlated with the presence of psoriatic arthritis,
presence of ANA or circulating CRP concentrations.
DISCUSSION
The main ﬁnding of this study is the low reliability of
these assay kits in determining AAA expression and
sADL trough levels. Multiple factors can contribute to
low assay reliability. Some are merely methodological:
the high number of false-positive results, as reported
elsewhere,21 22 and the low concordance of the results
after retesting in the current study indicating low speciﬁ-
city and possible external transitory interferences.
Others are clinical: a generally low occurrence of AAA
detected in this population of patients (16.7%), except
for frankly false-positive results, in addition to a low con-
cordance between AAA positivity and the clinical course
of the disease, as reﬂected by the changes in PASI scores
and the TNFα and CRP levels. A different situation
emerged when immunogenicity was detected in patients
previously exposed to ADL whose therapy was switched
to another biological due to secondary failure. In this
case, the prevalence of sAAA was 87%.
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Previous studies have investigated the expression of
ADAs in patients treated with different biological agents
for inﬂammatory and autoimmune diseases. Although
many were well-designed studies involving large, well-
characterised cohorts, the general experimental settings
were essentially the same: either one-time evaluation of
patients receiving the drug or longitudinal evaluation of
patients at the ﬁrst treatment and then again at 6 or 12
months.23 While the pioneering studies on the immuno-
genicity of biologicals did not take into account timing of
sampling, later research recognised this as an important
aspect and used samples taken just before drug adminis-
tration when circulating drug concentrations are lowest.
This holds particular importance because such assays are
inhibited by the presence of the drug in serum.22 24
Although the low speciﬁcity of these assays has been
repeatedly reported,21 to the best of our knowledge, no
studies to date have addressed this issue in practice. Here,
we aimed to overcome the principal limitations of previ-
ous studies in order to obtain a clearer picture of
immune response to biologicals, and of immunogenicity
of the anti-TNF agent ADL in particular.
To do this, we employed two complementary strategies:
sample retesting (for both ADL and AAA) in order to
conﬁrm (or reject) the test result and inclusion of sub-
jects (healthy and psoriatic) never treated with ADL as
negative controls. The second strategy sets out study apart
from previous studies in which the cohorts often
included patients treated with biologicals and patients
who, due to clinical needs, received concurrent treat-
ment with biologicals and ISs, which, however, are known
to modify the overall immunogenic response.18 25
Furthermore, we used a two-site (bridging) assay which,
along with radioimmunoassay (RIA) and antigen binding
test (ABT), is considered the most reliable test in this spe-
ciﬁc setting.26 The two-site assay is based on the ability of
antidrug IgGs (types 1, 2 and 3) to crosslink the antibody
molecule of the drug coated onto the plate and the
labelled antibody drug added to the reaction solution.
Although this assay is speciﬁc and sensitive, it does not
detect IgG4 due to their bi-speciﬁcity.27 In addition, we
measured serum TNF levels. Our rationale was that,
because TNF is the target of the anti-TNF agent, and
ADAs are, as claimed,28 neutralising against the drug,
TNF levels would be expected to rise. Therefore, it
appeared appropriate to measure TNF concentrations to
test the neutralising potential of eventual ADAs.
The main critical issues of this study are the small
sample size and the choice of the ELISA method to
detect sAAA. To address the former, we excluded
patients receiving concurrent IS–biological therapies,
which is a common practice in the treatment of psoria-
sis. In this way, we were able to select for cohorts that
were highly homogeneous, except for the subset of
patients with psoriatic arthritis. From a purely mathemat-
ical point of view, the statistical reliability was reduced
due to the low median PASI score, at least in group II,
and the small sample size, as was the correlation analysis
between an objective index (AAA) and a semi-
quantitative, well-validated but subjective index (PASI).
It is opinionable whether an objective index of disease
severity can be correlated with the putative index of
treatment analysed here. The second issue concerns the
choice of a standard ELISA method. This was dictated
by the need to use a method that is more likely to be
implemented in routine settings than RIA (due to radio-
activity) or in-house modiﬁcations of the ELISA protocol
(eg, pH-shift-anti-idiotype ABT,29 mobility-shift assay30).
Although the molecular structure of ADL is completely
of human origin, it can elicit an immune response in
some cases. The prevalence data on anti-ADL immuno-
genicity vary widely (0.04–87%),16 however, rendering
them clinically meaningless. When interpreting these
rates, it is important to note that the study reporting the
lower rate (0.04%) lasted only 4 weeks,31 which is a too
short a time for immunogenicity to develop,32 while the
one reporting the upper rate, although it lasted 45 weeks,
involved only 15 subjects.33 Our data indicate that the
immunogenicity potential of ADL locates in the lower
half of the range.
Our data substantiate previous reports of the preva-
lence of AAA. Despite the homogeneity of the cohorts
in our study, the exclusion of potential modifying factors
(ie, no IS cotreatment, same treatment doses and proto-
col) and testing at the time of sADL trough levels, we
found a wide quantitative variability in the laboratory
data. Moreover, the prevalence of AAA in our sample
was low. Finally, neither the serum TNFα concentration
nor the PASI score was associated with AAA expression
in the patients receiving ADL therapy.
What should be kept in mind is that immunogenicity
is a gradual process that develops and changes over
time. Continuation of treatment may induce either toler-
ance or stimulate further antibody production. Also, it
has been reported that antibodies against IFX or ADL
become undetectable in some patients on continuation
of treatment or dose escalation.34 35
The methodological considerations mentioned above,
and conﬁrmed here, along with the increasing number
of commercially available assays, explain the high vari-
ability of prevalence data, but they also considerably
limit the credibility of the data from clinical studies in
which ADAs are evaluated with assays developed by drug
companies, without providing complete information
about the technology used.
In conclusion, future research will need to investigate
the immunogenicity of biologicals according to protocols
that can provide a measurement of the reliability of the
assay used. For the time being, the reasons remain to be
elucidated for this low speciﬁcity (ie, the high number of
false-positive results) and the substances/situations pos-
sibly interfering with ADL/AAA measurement.
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